Gene editing therapies for genetic diseases
Pro Research Analysisby 
Searched over 200M research papers
Advances in Gene Editing Therapies for Genetic Diseases
Gene editing therapies have rapidly advanced, offering new hope for treating a wide range of genetic diseases by directly targeting and correcting the underlying genetic mutations. These therapies are transforming the landscape of precision medicine and have shown promise in both preclinical and clinical settings Deneault2024Cai2024Qie2025.
CRISPR-Cas9 and Other Gene Editing Technologies
The CRISPR-Cas9 system has emerged as a leading tool for precise and efficient genome editing. It allows scientists to target specific DNA sequences and make corrections, deletions, or insertions, which is especially valuable for treating inherited genetic disorders Deneault2024Cai2024Abdelnour2021+2 MORE. Other gene editing platforms, such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), have also been used, but CRISPR-Cas9 stands out for its higher efficiency and specificity Maeder2016Shim2017Harisa2023.
Recent innovations have expanded the CRISPR toolkit to include Cas12 and Cas13 variants, enabling more complex and diverse genetic modifications . These advancements have broadened the range of treatable genetic conditions, from single-gene (monogenic) disorders to more complex diseases Deneault2024Cai2024.
Prime Editing: A New Frontier
Prime editing is a newer gene editing technology that builds on CRISPR-Cas9. It can introduce all types of base-to-base conversions, as well as targeted insertions and deletions, with high precision and fewer off-target effects Deneault2024Godbout2023. Prime editing has shown promise in preclinical studies for diseases affecting the liver, eye, skin, muscles, and nervous system, as well as for conditions like cystic fibrosis, beta-thalassemia, and X-linked severe combined immunodeficiency .
Delivery Systems for Gene Editing Therapies
Efficient and safe delivery of gene editing tools into target cells is a major challenge. Both viral vectors (such as adeno-associated viruses) and non-viral methods (like nanoparticles and extracellular vesicles) are being explored to improve delivery efficiency and minimize immune responses Deneault2024Shim2017Harisa2023. Optimizing these delivery systems is crucial for the success of gene editing therapies in clinical applications Qie2025Shim2017.
Clinical Applications and Successes
Gene editing therapies are being tested in clinical trials for a variety of genetic diseases. For example, ex vivo gene editing of hematopoietic stem cells has been used to treat beta-thalassemia and sickle cell disease by inducing the production of fetal hemoglobin . In primary immunodeficiency diseases, gene editing has shown the ability to correct genetic defects and restore immune function . Other applications include cancer immunotherapy, where gene editing is used to enhance the effectiveness of T cell-based treatments .
Challenges and Ethical Considerations
Despite significant progress, several challenges remain. These include the risk of off-target effects, limitations in delivery methods, immune responses, and the need for long-term safety data Deneault2024Cai2024Qie2025+2 MORE. Ethical and regulatory concerns, especially regarding the potential for unintended genetic changes and the use of gene editing in embryos, require careful consideration and ongoing oversight Deneault2024Cai2024Shim2017+1 MORE.
Conclusion
Gene editing therapies represent a major breakthrough in the treatment of genetic diseases, offering the potential for precise, long-lasting, and even curative interventions. Technologies like CRISPR-Cas9 and prime editing are at the forefront, with ongoing research focused on improving safety, delivery, and ethical frameworks. Continued advancements in this field are expected to expand the range of treatable conditions and bring gene editing therapies closer to routine clinical use Deneault2024Cai2024Qie2025+7 MORE.
Sources and full results
Most relevant research papers on this topic
Prime Editing for Human Gene Therapy: Where Are We Now?
Prime editing for human gene therapy shows promise in treating inherited diseases by correcting genetic mutations, with potential applications in liver, eye, skin, muscular, and neurodegenerative diseases.
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
Gene editing technologies like CRISPR, TALENs, and ZFNs show promise in treating various human diseases, including cancer, HPV-related cervix carcinoma, HIV, β-thalassemia, sickle cell disease, hemophilia, and Leber's congenital amaurosis.
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases
CRISPR/Cas9 technology shows potential for treating inherited diseases by editing DNA structures and changing gene function, with potential applications in gene therapy and treating untreatable disorders.
Genome-editing Technologies for Gene and Cell Therapy
Genome-editing technologies enable precise manipulation of human genomes for therapeutic effects in gene and cell therapy, offering potential for antiviral strategies, immunotherapies, and treating monogenic hereditary disorders.
Molecular tumor targeting of gelonin by fusion with F3 peptide
Gene-editing therapies show promise for treating various diseases, but precise engineering and delivery of nucleases pose regulatory challenges and safety concerns.
DOI